TC Biopharm

TC BioPharm is a clinical-stage biopharmaceutical company specializing in developing gamma-delta (γδ) T cell therapies for cancer treatment and other indications. The company's lead product, OmnImmune, is an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells targeting acute myeloid leukemia (AML). The company's technology leverages the natural ability of γδ T cells to recognize and target diseased cells through their detection of isopentenyl pyrophosphates (IPP), which are expressed by cancer cells but not healthy cells. TC BioPharm has developed a proprietary manufacturing process that enables the production of allogeneic cell therapies at a significantly lower cost of USD 300-500 per dose, compared to industry standards of USD 250,000-USD 500,000. In March 2022, the company reported positive Phase 1 billion/2a data for OmnImmune in late-stage AML patients, with 50% of patients in the higher dose cohort achieving complete responses. The company has streamlined its manufacturing process by eliminating approximately 200 steps and reducing hands-on manufacturing time by half, enabling batch manufacturing of approximately 300 doses that can be frozen for years. TC BioPharm utilizes its proprietary CryoTC technology to provide frozen product to clinics worldwide. In October 2023, the company partnered with Excellos, a San Diego-based CDMO, to support its US clinical trial expansion efforts.In March 2024, the company is advancing its ACHIEVE Phase 2 billion clinical trial in the UK, with successful administration of higher dose levels to multiple patients. The company is also expanding its platform through new initiatives, including development of a streamlined manufacturing process aimed at increasing treatment capacity from 52 to over 1,000 patient treatments per year with an expected 85% cost reduction per patient. In October 2024, TC BioPharm announced a partnership with Carnegie Mellon University to develop an artificial intelligence solution for optimizing donor screening and matching processes.

Key customers and partnerships

TC BioPharm has established several strategic partnerships to advance its clinical programs. In October 2023, the company partnered with Excellos, a San Diego-based CDMO, to provide allogeneic cell banks for its US clinical trials. In October 2024, the company entered into a sponsored research agreement with Carnegie Mellon University's Dr. Wei Wu to develop AI solutions for donor selection and matching processes. The company has also received FDA clearance for its IND application to begin clinical studies of TCB008 (OmnImmune) in the US for treating relapse/refractory AML.